Acetorphine is a synthetic narcotic analgesic. Acetorphine was reported to have uses in veterinary medicine with pronounced advantages in the immobilization of the giraffe in which toxic effects were reduced as compared to the effects of etorphine. In July 1966, the Director-General of the World Health Organization informed the Secretary-General that WHO had arrived at the conclusion that etorphine and acetorphine should be included in Schedule I of the Convention, since they could give rise to similar abuse, and produce similar ill effects as the substances already listed therein. Acetorphine is a Schedule I controlled substance in the United States.

Ceftioxide is broad-spectrum , beta-lactam antibiotic patented by German pharmaceutical company Hoechst A.-G.

Dacisteine is a derivative of a N-acetylcysteine, where a second acetyl group is attached to a sulfur atom. Dacisteine is marketed in France under tradename Mucothiol for the treatment of disorders of bronchial secretion, acute bronchitis and acute episode of chronic bronchopneumopathies. Dacisteine exerts its action on the gel phase of the mucus, presumably by breaking the disulfide bonds of the glycoproteins, and thus promotes the expectoration.

Talosalate, a phthalidyl ester of acetylsalicylic acid, was used as an analgesic and anti-inflammatory agent. Talosalate was studied in preclinical experiments for the treatment of inflammation and rheumatic disorder in Argentina. However, the further development of the drug appears to have been discontinued.

Aceburic acid is the acetyl ester of gamma-hydroxybutyrate (GHB), it has analgesic effects as a prodrug to GHB. GHB is used medically as an anesthetic as well as a treatment for several neurologically affecting diseases.

Dacuronium is an aminosteroid, acting as a competitive antagonist of nicotinic acetylcholine receptors. In animals, dacuronium worked as a short-acting muscle relaxant with a rapid onset of action. In a clinical trial, dacuronium was markedly less potent than tubocurarine and did not show a rapid recovery from its action.

Cloximate is a non-steroidal anti-inflammatory drug, developed in the Dutch company Philips-Duphar B.V. Research Laboratories in the 1970s. Cloximate acts by inhibition of PGE2 biosynthesis. In preclinical experiments, cloximate showed good inhibitory activities in local exudative tests, in the proliferative and functional aspects of experimental inflammation, as well as in the bradykinin-evoked bronchoconstriction test. Cloximate showed almost no harmful effects on the gastrointestinal mucosa and no influence upon the emptying rate of the stomach. Cloximate was evaluated in double-blind clinical trials, where different formulations were compared with naproxen. Gastrointestinal blood loss increased more in the naproxen group than in the group treated with non-enteric coated cloximate.

Espatropate (UK 88060) is an antagonist of M3 muscarinic receptors. Espatropate is a bronchodilator with anticholinergic activity. It was undergoing preclinical development with Pfizer for the treatment of asthma.